Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs HubSpot Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while HubSpot Inc trades at $229.3 (market cap $11.56B). The key difference: Halozyme Therapeutics Inc. Common Stock and HubSpot Inc are close in size by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and HubSpot Inc for 78 Days on average.
| HALO | HUBS | |
|---|---|---|
Market Cap | $12.58B | $11.56B |
Volume | 2,179,278 | 1,891,287 |
Sector | Health | Technology |
52-Week High | $115.22 | $494.58 |
52-Week Low | $61.63 | $170.39 |
Typical Hold Time | 1 Days | 78 Days |
Enterprise Value | $14.49B | $10.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HubSpot (HUBS) trades at $228.96, up 3.93% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth, reaching $3.13B in 2025 with net income turning positive at $45.91M. Recent analyst day highlighted AI strategy enhancements and margin expansion targets, while institutional buying and positive earnings beats support investor confidence. Technical indicators show the stock trading near pivot point resistance at $228 with RSI suggesting potential overbought conditions.
Outlook remains positive with 57% analyst buy ratings and $243.65 consensus target, though high P/E of 82.5x demands sustained growth execution. Key risks include AI competition pressure and valuation sensitivity to earnings momentum. The transition to profitability and strong cash flow generation provide fundamental support for continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
